AR and metastatic prostate carcinoma: However, in patients with metastatic prostate cancer, using GM-CSF as an adjuvant in the DNA vaccine encoding the androgen receptor ligand-binding domain (pTVG-AR, MVI-118) had no additional therapeutic benefit than the vaccine alone (108).